|
1
|
Schofield AV and Bernard O: Rho-associated
coiled-coil kinase (ROCK) signaling and disease. Crit Rev Biochem
Mol Biol. 48:301–316. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Amin E, Dubey BN, Zhang SC, Gremer L,
Dvorsky R, Moll JM, Taha MS, Nagel-Steger L, Piekorz RP, Somlyo AV
and Ahmadian MR: Rho-kinase: Regulation, (dys) function and
inhibition. Biol Chem. 394:1399–1410. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Satoh K, Fukumoto Y and Shimokawa H:
Rho-kinase: Important new therapeutic target in cardio-vascular
diseases. Am J Physiol Heart Circ Physiol. 301:H287–H296. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hahmann C and Schroeter T: Rho-kinase
inhibitors as therapeutics: From pan inhibition to isoform
selectivity. Cell Mol Life Sci. 67:171–177. 2010. View Article : Google Scholar
|
|
5
|
Olson MF: Applications for ROCK kinase
inhibition. Curr Opin Cell Biol. 20:242–248. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shi J and Wei L: Rho kinase in the
regulation of cell death and survival. Arch Immunol Ther Exp
(Warsz). 55:61–75. 2007. View Article : Google Scholar
|
|
7
|
Ming D, Yan BP, Liao JK, Lam YY, Yip GW
and Yu CM: Rho-kinase inhibition: A novel therapeutic target for
the treatment of cardiovascular diseases. Drug Discov Today.
15:622–629. 2010. View Article : Google Scholar
|
|
8
|
Budzyn K, Marley PD and Sobey CG:
Targeting Rho and Rho-kinase in the treatment of cardiovascular
disease. Trends Pharmacol Sci. 27:97–104. 2006. View Article : Google Scholar
|
|
9
|
Shimokawa H and Rashid M: Development of
Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol
Sci. 28:296–302. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kushiyama T, Oda T, Yamamoto K, Higashi K,
Watanabe A, Takechi H, Uchida T, Oshima N, Sakurai Y, Miura S and
Kumagai H: Protective effects of Rho kinase inhibitor fasudil on
rats with chronic kidney disease. Am J Physiol Renal Physiol.
304:F1325–F1334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nishikimi T, Koshikawa S, Ishikawa Y,
Akimoto K, Inaba C, Ishimura K, Ono H and Matsuoka H: Inhibition of
Rho-kinase attenuates nephrosclerosis and improves survival in
salt-loaded spontaneously hypertensive stroke-prone rats. J
Hypertens. 25:1053–1063. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kanda T, Wakino S, Hayashi K, Homma K,
Ozawa Y and Saruta T: Effect of fasudil on Rho-kinase andv
nephropathy in subtotally nephrectomized spontaneously hypertensive
rats. Kidney Int. 64:2009–2019. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xie X, Peng J, Chang X, Huang K, Huang J,
Wang S, Shen X, Liu P and Huang H: Activation of RhoA/ROCK
regulates NF-κB signaling pathway in experimental diabetic
nephropathy. Mol Cell Endocrinol. 369:86–97. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou H, Li YJ, Wang M, Zhang LH, Guo BY,
Zhao ZS, Meng FL, Deng YG and Wang RY: Involvement of RhoA/ROCK in
myocardial fibrosis in a rat model of type 2 diabetes. Acta
Pharmacol Sin. 32:999–1008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rikitake Y, Oyama N, Wang CY, Noma K,
Satoh M, Kim HH and Liao JK: Decreased perivascular fibrosis but
not cardiac hypertrophy in ROCK1+/-haploinsufficient mice.
Circulation. 112:2959–2965. 2005.PubMed/NCBI
|
|
16
|
Li Q, Xu Y, Li X, Guo Y and Liu G:
Inhibition of Rho-kinase ameliorates myocardial remodeling and
fibrosis in pressure overload and myocardial infarction: Role of
TGF-β1-TAK1. Toxicol Lett. 211:91–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun GP, Kohno M, Guo P, Nagai Y, Miyata K,
Fan YY, Kimura S, Kiyomoto H, Ohmori K, Li DT, et al: Involvements
of Rho-kinase and TGF-beta pathways in aldosterone-induced renal
injury. J Am Soc Nephrol. 17:2193–2201. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagatoya K, Moriyama T, Kawada N, Takeji
M, Oseto S, Murozono T, Ando A, Imai E and Hori M: Y-27632 prevents
tubulointerstitial fibrosis in mouse kidneys with unilateral
ureteral obstruction. Kidney Int. 61:1684–1695. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Satoh S, Yamaguchi T, Hitomi A, Sato N,
Shiraiwa K, Ikegaki I, Asano T and Shimokawa H: Fasudil attenuates
interstitial fibrosis in rat kidneys with unilateral ureteral
obstruction. Eur J Pharmacol. 455:169–174. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang YM, Bo J, Taffet GE, Chang J, Shi J,
Reddy AK, Michael LH, Schneider MD, Entman ML, Schwartz RJ and Wei
L: Targeted deletion of ROCK1 protects the heart against pressure
overload by inhibiting reactive fibrosis. FASEB J. 20:916–925.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou L, Liu F, Huang XR, Chen H, Chung AC,
Shi J, Wei L, Lan HY and Fu P: Amelioration of albuminuria in ROCK1
knockout mice with streptozotocin-induced diabetic kidney disease.
Am J Nephrol. 34:468–475. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Okamoto R, Li Y, Noma K, Hiroi Y, Liu PY,
Taniguchi M, Ito M and Liao JK: FHL2 prevents cardiac hypertrophy
in mice with cardiac-specific deletion of ROCK2. FASEB J.
27:1439–1449. 2013. View Article : Google Scholar :
|
|
23
|
Fu P, Liu F, Su S, Wang W, Huang XR,
Entman ML, Schwartz RJ, Wei L and Lan HY: Signaling mechanism of
renal fibrosis in unilateral ureteral obstructive kidney disease in
ROCK1 knockout mice. J Am Soc Nephrol. 17:3105–3114. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thumkeo D, Keel J, Ishizaki T, Hirose M,
Nonomura K, Oshima H, Oshima M, Taketo MM and Narumiya S: Targeted
disruption of the mouse Rho-associated kinase 2 gene results in
intrauterine growth retardation and fetal death. Mol Cell Biol.
23:5043–5055. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Woessner JF: The determination of
hydroxyproline in tissue and protein samples containing small
proportions of this imino acid. Arch Biochem Biophys. 93:440–447.
1961. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kivirikko KI, Laitinen O and Prockop DJ:
Modifications of a specific assay for hydroxyproline in urine. Anal
Biochem. 19:249–255. 1967. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Y: Epithelial to mesenchymal
transition in renal fibrogenesis: Pathologic significance,
molecular mechanism and therapeutic intervention. J Am Soc Nephrol.
15:1–12. 2004. View Article : Google Scholar
|
|
28
|
Piera-Velazquez S, Li Z and Jimenez SA:
Role of endothelial-mesenchymal transition (EndoMT) in the
pathogenesis of fibrotic disorders. Am J Pathol. 179:1074–1080.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Duffield JS: Cellular and molecular
mechanisms in kidney fibrosis. J Clin Invest. 124:2299–2306. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Patel S, Takagi KI, Suzuki J, Imaizumi A,
Kimura T, Mason RM, Kamimura T and Zhang Z: RhoGTPase activation is
a key step in renal epithelial mesenchymal transdifferentiation. J
Am Soc Nephrol. 16:1977–1984. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rodrigues-Díez R, Carvajal-González G,
Sánchez-López E, Rodríguez-Vita J, Rodrigues Díez R, Selgas R,
Ortiz A, Egido J, Mezzano S and Ruiz-Ortega M: Pharmacological
modulation of epithelial mesenchymal transition caused by
angiotensin II. Role of ROCK and MAPK pathways. Pharm Res.
25:2447–2461. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tamura M, Nakao H, Yoshizaki H,
Shiratsuchi M, Shigyo H, Yamada H, Ozawa T, Totsuka J and Hidaka H:
Development of specific Rho-kinase inhibitors and their clinical
application. Biochim Biovphys Acta. 1754:245–252. 2005. View Article : Google Scholar
|
